Cytomx Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cytomx Therapeutics, Inc. on March 4, 2021, reporting events that occurred on February 26, 2021. The filing addresses Item 5.02 regarding the compensatory arrangements of certain officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details executive compensation adjustments approved by the Compensation Committee and the Board of Directors.
Material Changes
The primary material change reported is the approval of 2021 annual base salaries and 2020 cash performance bonuses for three named executive officers:
- Sean A. McCarthy (President, CEO, and Chairman): Received a salary increase of $20,825, resulting in a 2021 base salary of $615,825. He was awarded a 2020 cash bonus of $357,000.
- Amy Peterson, M.D. (EVP, Chief Development Officer): Received a salary increase of $17,605, resulting in a 2021 base salary of $520,605. She was awarded a 2020 cash bonus of $301,800.
- Lloyd Rowland (SVP, General Counsel): Received a salary increase of $14,128, resulting in a 2021 base salary of $417,778. He was awarded a 2020 cash bonus of $161,460.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business strategy, risks, contingencies, or unusual items beyond the compensation approvals.
Investor Verification Checklist
- Verify the total cash outflow for the approved 2020 bonuses ($820,260) against the company's current cash position in the most recent 10-Q or 10-K.
- Confirm the effective date of the 2021 salary increases to understand the impact on the 2021 operating expense budget.
- Review the company's most recent financial statements to assess the ratio of executive compensation to total operating expenses.